


PHARMACEUTICAL 2017

ASAVARA

Savara Inc Rank 288 of 313





PHARMACEUTICAL 2017

Savara Inc Rank 288 of 313



The relative strengths and weaknesses of Savara Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Savara Inc compared to the market average is the variable Cost of Goods Sold, increasing the Economic Capital Ratio by 21% points. The greatest weakness of Savara Inc is the variable Net Income, reducing the Economic Capital Ratio by 563% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,041%, being 625% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	12,185
Cost of Goods Sold	0
Intangible Assets	3,007
Liabilities, Current	4,866
Liabilities, Non-Current	0
Other Assets	2,631
Other Compr. Net Income	18
Other Expenses	6,172
Other Liabilities	3,297
Other Net Income	79
Property and Equipment	99
Research and Development	20,793
Revenues	128
Selling, General and Administrative Expense	9,342

Output Variable	Value in 1000 USD
Assets	17,922
Liabilities	8,163
Expenses	36,307
Stockholders Equity	9,759
Net Income	-36,100
Comprehensive Net Income	-36,091
Economic Capital Ratio	-1,041%